Tags

Type your tag names separated by a space and hit enter

Radiotherapy for extramedullary plasmacytoma of the head and neck.
Int J Radiat Oncol Biol Phys. 2009 Mar 01; 73(3):789-94.IJ

Abstract

PURPOSE

To define the effectiveness of radiotherapy in the treatment of patients with extramedullary plasmacytoma of the head and neck (EMPHN).

METHODS AND MATERIALS

We searched the Mayo Clinic Rochester Department of Radiation Oncology electronic Tumor Registry and identified 18 consecutive patients with a diagnosis of solitary EMPHN. Sixteen patients were treated with radiotherapy at initial diagnosis and 2 received salvage radiotherapy for local failure after surgery. Median dose administered was 50.4 Gy. Median follow-up was 6.8 years.

RESULTS

One patient (6%) developed a marginal recurrence 12 months after treatment. Six patients (33%) developed multiple myeloma (2 patients) or plasmacytomas at distant sites (4 patients) at a median of 3.1 years after diagnosis (range, 0.02 to 9.6 years). Median and 5- and 10-year overall survival rates from the date of diagnosis are 12.5 years, 88%, and 55%, respectively. Two patients (11%) developed a radiation-induced malignancy at 6.5 and 6.9 years after treatment.

CONCLUSIONS

Radiotherapy provides excellent local and regional tumor control and survival in patients with EMPHN. To the best of our knowledge, this is the first report of presumed radiation-induced malignancy in this patient population.

Authors+Show Affiliations

Graduate Medical Education-Translational Year Program, Saint John's Mercy Medical Center, St Louis, MO, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18707826

Citation

Creach, Kimberly M., et al. "Radiotherapy for Extramedullary Plasmacytoma of the Head and Neck." International Journal of Radiation Oncology, Biology, Physics, vol. 73, no. 3, 2009, pp. 789-94.
Creach KM, Foote RL, Neben-Wittich MA, et al. Radiotherapy for extramedullary plasmacytoma of the head and neck. Int J Radiat Oncol Biol Phys. 2009;73(3):789-94.
Creach, K. M., Foote, R. L., Neben-Wittich, M. A., & Kyle, R. A. (2009). Radiotherapy for extramedullary plasmacytoma of the head and neck. International Journal of Radiation Oncology, Biology, Physics, 73(3), 789-94. https://doi.org/10.1016/j.ijrobp.2008.04.077
Creach KM, et al. Radiotherapy for Extramedullary Plasmacytoma of the Head and Neck. Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):789-94. PubMed PMID: 18707826.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Radiotherapy for extramedullary plasmacytoma of the head and neck. AU - Creach,Kimberly M, AU - Foote,Robert L, AU - Neben-Wittich,Michelle A, AU - Kyle,Robert A, Y1 - 2008/08/15/ PY - 2008/02/22/received PY - 2008/04/25/revised PY - 2008/04/29/accepted PY - 2008/8/19/pubmed PY - 2009/3/4/medline PY - 2008/8/19/entrez SP - 789 EP - 94 JF - International journal of radiation oncology, biology, physics JO - Int J Radiat Oncol Biol Phys VL - 73 IS - 3 N2 - PURPOSE: To define the effectiveness of radiotherapy in the treatment of patients with extramedullary plasmacytoma of the head and neck (EMPHN). METHODS AND MATERIALS: We searched the Mayo Clinic Rochester Department of Radiation Oncology electronic Tumor Registry and identified 18 consecutive patients with a diagnosis of solitary EMPHN. Sixteen patients were treated with radiotherapy at initial diagnosis and 2 received salvage radiotherapy for local failure after surgery. Median dose administered was 50.4 Gy. Median follow-up was 6.8 years. RESULTS: One patient (6%) developed a marginal recurrence 12 months after treatment. Six patients (33%) developed multiple myeloma (2 patients) or plasmacytomas at distant sites (4 patients) at a median of 3.1 years after diagnosis (range, 0.02 to 9.6 years). Median and 5- and 10-year overall survival rates from the date of diagnosis are 12.5 years, 88%, and 55%, respectively. Two patients (11%) developed a radiation-induced malignancy at 6.5 and 6.9 years after treatment. CONCLUSIONS: Radiotherapy provides excellent local and regional tumor control and survival in patients with EMPHN. To the best of our knowledge, this is the first report of presumed radiation-induced malignancy in this patient population. SN - 1879-355X UR - https://www.unboundmedicine.com/medline/citation/18707826/Radiotherapy_for_extramedullary_plasmacytoma_of_the_head_and_neck_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0360-3016(08)00825-0 DB - PRIME DP - Unbound Medicine ER -